Main topics
PHARMAnetwork.digital - magazine - N°58 - September 2023
CDMOs: Financial performance H1 2023
PHARMAnetwork.digital - magazine - N°58 - September 2023
EU Commission’s proposed changes to marketing authorisation procedures
PHARMAnetwork.digital - magazine - N°58 - September 2023
Big pharma’s new life without Covid-19 products
PHARMAnetwork.digital - magazine - N°58 - September 2023
Biotech industry: between challenges and optimism
PHARMAnetwork.digital - magazine - N°57 - Mai 2023
Building a new framework for European pharmaceutical legislation
PHARMAnetwork.digital - magazine - N°57 - Mai 2023
Artificial intelligence in pharmaceutical development and manufacturing
PHARMAnetwork.digital - magazine - N°57 - Mai 2023
What potential for biosimilars in healthcare systems?
PHARMAnetwork.digital - magazine - N°56 - February 2023
Medicines: Headed for the Great Shortage?
PHARMAnetwork.digital - magazine - N°56 - February 2023
The Intellectual Property clause in pharmaceutical subcontracting agreements
PHARMAnetwork.digital - magazine - N°56 - February 2023
To repackage or not? Latest CJEU rulings provide guidance for parallel traders of medicines
PHARMAnetwork.digital - magazine - N°55 - November 2022
Protection expiry in Europe: facts and figures
PHARMAnetwork.digital - magazine - N°55 - November 2022
BIO CDMOs: Time for big investments
PHARMAnetwork.digital - magazine - N°55 - November 2022
Nanothechnology in the healthcare
PHARMAnetwork.digital - magazine - N°54 - September 2022
CDMO CEOs: Visions and strategies for 2022 and after
PHARMAnetwork.digital - magazine - N°54 - September 2022
CLINICAL TRIALS ON MEDICINAL PRODUCTS: Overview of the new legal regimes
PHARMAnetwork.digital - magazine - N°53 - June 2022